A leading incubator for cancer treatment innovations with a focus on the diagnosis and treatment of multiple myeloma, other B-cell malignancies and related disorders

  • ONCOtracker, Inc. is a West Hollywood-based oncology company pursuing intellectual property for innovative treatments leading to dramatically improved outcomes.
  • We have exclusive rights to a Serum B-Cell Maturation Antigen (sBCMA) blood test, which is being developed to monitor tumor burden and predict the therapeutic outcome of multiple myeloma patients.
  • sBCMA is being investigated for clinical application in chronic lymphocytic leukemia, B-cell lymphoma and select solid tumor malignancies.
  • ONCOtracker has intellectual property related to novel treatment approaches for multiple myeloma, which are being pursued in ongoing clinical trials.

Our Areas of Focus

Serum BCMA Testing & Services

Novel serum B-cell marker for multiple myeloma and possibly other cancers and diseases. ONCOtracker’s sBCMA assay is used in pre-clinical, phase I and II studies investigating response to drug therapies.

Testing & Services

Janus Kinase Inhibitors

Patent issued for combination of JAKi’s with immunomodulatory agents for anti-cancer applications.

Explore Licensing

Gamma Secretase Inhibitors

Patent pending for use-case of GSI as a treatment potentiator for BCMA-targeted therapies to treat multiple myeloma.

Explore Licensing

Precision Medicine

A transformative innovator in enabling data-driven treatment decisions to improve outcomes for cancer patients and reduce the cost of care.

Coming Soon

How can we help you?